Prescription Weight Management Treatment

Saxenda® (liraglutide) Injection 6mg/3mL is a prescription-only medication used to support chronic weight management in adults with obesity or in individuals who are overweight and have weight-related health conditions. It is intended to be used alongside a reduced-calorie diet, increased physical activity, and ongoing medical supervision.

Rather than offering a quick solution, Saxenda forms part of a long-term treatment strategy designed to help patients develop healthier eating habits and achieve gradual, sustainable weight loss. Its effectiveness has been evaluated in clinical studies, where it has been shown to improve weight-loss outcomes when combined with lifestyle changes.

What Is Saxenda (Liraglutide)?

Saxenda contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring hormone involved in regulating appetite, food intake, and blood sugar levels.

By mimicking the action of this hormone, Saxenda helps reduce calorie intake by influencing the body’s natural appetite control mechanisms.

How Saxenda Works

Saxenda helps support weight management through several mechanisms, including:

• Reducing hunger throughout the day
• Increasing feelings of fullness after eating
• Helping decrease food cravings
• Slowing stomach emptying
• Supporting healthier portion control

These effects can make it easier for patients to maintain a calorie-controlled eating plan while working toward long-term weight-management goals.

Who May Be Prescribed Saxenda?

A healthcare professional may prescribe Saxenda for adults who meet specific clinical criteria, including:

• A Body Mass Index (BMI) of 30 kg/m² or greater (obesity)

or

• A BMI of 27 kg/m² or greater (overweight) together with at least one weight-related medical condition, such as:
  • High blood pressure
  • Type 2 diabetes
  • High cholesterol
  • Obstructive sleep apnoea
  • Other obesity-related health conditions

Treatment should begin only after a qualified healthcare provider has determined that Saxenda is appropriate for the individual’s medical needs.

Saxenda Injection Pen

Saxenda is supplied as a prefilled injection pen containing 6 mg of liraglutide in 3 mL of solution.

It is administered once daily by subcutaneous injection beneath the skin.

Common injection sites include:

• Abdomen
• Front of the thigh
• Upper arm

Treatment typically starts with a low dose that is increased gradually over several weeks. This stepwise approach helps minimise gastrointestinal side effects while allowing the body time to adapt to the medication.

Patients should receive proper training from a healthcare professional before self-administering the injection.

Potential Benefits of Saxenda

When used together with healthy lifestyle modifications, Saxenda may help:

• Reduce appetite
• Increase satiety after meals
• Support clinically significant weight loss
• Improve adherence to a calorie-controlled diet
• Assist with blood sugar regulation
• Lower certain obesity-related health risks

Clinical research has shown that patients using Saxenda alongside diet and exercise generally achieve greater weight loss than those relying on lifestyle changes alone.

Important Safety Information

Saxenda is not suitable for everyone and should only be used under medical supervision.

Do not use Saxenda if you:

• Have a personal or family history of medullary thyroid carcinoma (MTC)
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Are allergic to liraglutide or any ingredient contained in Saxenda

Animal studies identified an increased risk of thyroid C-cell tumours. Although this risk has not been established in humans, the prescribing information includes an important precaution. Patients should discuss their full medical history with their healthcare provider before starting treatment.

Understanding MEN 2

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a rare inherited condition affecting hormone-producing glands. Individuals with this condition have an increased risk of developing medullary thyroid carcinoma.

For this reason, Saxenda should not be prescribed to patients with MEN 2 or those who have a personal or family history of medullary thyroid cancer.

Healthcare professionals routinely evaluate patients for these risk factors before initiating treatment.

Correct Administration

Saxenda is intended only for subcutaneous injection.

It should never be injected:

• Into a vein
• Into a muscle

Using the medication correctly helps ensure consistent absorption and reduces the risk of complications. Patients should carefully follow the instructions provided by their healthcare professional.

Possible Side Effects

As with all prescription medicines, Saxenda may cause side effects.

Common side effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Headache
• Fatigue
• Reduced appetite
• Indigestion

These reactions are often mild and tend to improve as the body adjusts to treatment.

Less common but potentially serious side effects include:

• Pancreatitis
• Gallbladder disease
• Kidney problems
• Serious allergic reactions
• Increased heart rate

Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, difficulty breathing, swelling of the face or throat, or other symptoms of a serious allergic reaction.

Healthy Lifestyle Habits Matter

Saxenda works best as part of a comprehensive weight-management programme.

Healthcare providers generally recommend combining treatment with:

• A balanced, calorie-controlled diet
• Regular physical activity
• Good sleep habits
• Stress management
• Ongoing medical follow-up

Medication is intended to complement—not replace—healthy lifestyle choices.

Regular Medical Monitoring

Patients taking Saxenda should attend scheduled follow-up appointments throughout treatment.

Healthcare providers may monitor:

• Weight-loss progress
• Blood glucose levels
• Blood pressure
• Treatment response
• Side effects
• Dose adjustments when necessary

Regular monitoring helps maximise treatment benefits while supporting patient safety.

Conclusion

Saxenda (Liraglutide) Injection 6mg/3mL is a clinically established prescription treatment for long-term weight management in eligible adults. By helping reduce appetite, increase feelings of fullness, and support healthier eating habits, it can play an important role in a medically supervised weight-management plan.

However, Saxenda is not suitable for everyone and should only be used under the guidance of a qualified healthcare professional. Before starting treatment, patients should discuss their medical history, including any history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or medullary thyroid carcinoma, to ensure the medication is appropriate for their individual circumstances.

When combined with healthy lifestyle changes and regular medical follow-up, Saxenda may help eligible patients work toward sustainable weight-management goals while supporting their overall health.